Biodesix, Inc. (BDSX) vs Keros Therapeutics, Inc. (KROS)
A side-by-side comparison of Biodesix, Inc. and Keros Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BDSX
Biodesix, Inc.
$29.55HealthcareDelayed quote: Oct 6, 2026, 10:08 AM EDT
KROS
Keros Therapeutics, Inc.
$11.46HealthcareDelayed quote: Oct 6, 2026, 10:04 AM EDT
Total return — BDSX vs KROS
growth of $100 · dividends reinvested · last 6yBDSX -88.7% (-30.4%/yr)KROS -80.3% (-23.7%/yr)KROS compounded faster over this window
BDSX KROS
BDSX vs KROS: by the numbers
- •BDSX is the larger company ($241M vs $227M market cap).
- •Both run net losses; BDSX's is the smaller (-26.97% vs -553.88% net margin).
- •KROS grew revenue faster over the past five years (172.50% vs 5.99% CAGR).
Metrics side by side
Valuation
| Metric | BDSX | KROS |
|---|---|---|
| P/S ratio | 2.34 | 15.13 |
| P/B ratio | 26.30 | 0.87 |
Profitability
| Metric | BDSX | KROS |
|---|---|---|
| Gross margin | 82.50% | 94.68% |
| Operating margin | -31.37% | 28.94% |
| Net margin | -26.97% | -553.88% |
| ROE | -303.61% | -31.70% |
| ROIC | -25.73% | -36.49% |
Growth (annualized)
| Metric | BDSX | KROS |
|---|---|---|
| Revenue CAGR (5Y) | 5.99% | 172.50% |
| Total return CAGR (5Y) | -28.49% | -21.98% |
Frequently asked
- Which has grown faster, BDSX or KROS?
- Over the past five years, KROS grew revenue faster — BDSX at a 5.99% CAGR versus KROS at 172.50%.
- How have BDSX and KROS total returns compared?
- Over the past 5 years, BDSX delivered -28.49% and KROS delivered -21.98% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Biodesix ROEKeros Therapeutics ROEBiodesix operating marginKeros Therapeutics operating marginBiodesix revenue growthKeros Therapeutics revenue growthBiodesix free cash flowKeros Therapeutics free cash flow
Biodesix & Keros Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.